News
PROTEINS IN PROFILE: VIRAL ANTIGEN PROTEINS
The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is a key target in COVID-19 vaccine development, but its complex…
UNLOCKING NOVEL CANCER TARGETS WITH ALiCE®
Cell-Free Protein Synthesis with ALiCE® Delivers a Functional, Native-Like Membrane Receptor Tyrosine Kinase
Receptor tyrosine kinases (RTKs) are proteins of…
PROTEIN IN PROFILE: RAPID PRODUCTION OF A BI-SPECIFIC ANTIBODY
Discover how the ALiCE® cell-free expression platform simplifies the production of bispecific and multispecific antibodies, achieving expression in just 24–48…
HARNESSING THE POWER OF MULTISPECIFIC ANTIBODIES
A Conversation with LenioBio’s Dr. Ridhima Gomkale
In the rapidly evolving landscape of immunotherapies, multispecific antibodies have emerged as a…